Prognosis and epidemiology relapsed/refractory follicular lymphoma
The prognosis and epidemiology of relapsed and refractory follicular lymphoma have not been well documented, as most states concentrate on follicular lymphoma as a whole. In itself, this article includes some references concerning follicular lymphoma, with a few small groups on the relapsed and refractory forms of the disease.
Prognostic factors
For patients with follicular lymphoma, the general five-year survival rate is approximately 72-77% and the median survival regimen occurs just below 10 years. However, the current prognosis regimes are expected to be higher than that indicated in the previous research, due to the introduction of new and targeted therapies such as rituximab.
Patients with relapsed or refractory follicular lymphoma have a lower prognosis than those with follicular lymphoma that successfully reach remission for an extended period of time. The use of targeted claims such as rituximab has improved remission rates.
Factor that can influence the prognosis for the patient include age, lymphoma severity, hemoglobin count, lymph node involvement, and LDH level. These factors were compiled together to produce a prognostic index, as described below.
International prognostic Index of follicular lymphoma (FLIPI)
The international prognostic Index of follicular lymphoma (FLIPI) is used to identify patients it is most likely to respond that well to the claim and those it is most likely to relapse that, based on prognostic factors. The following factors are considered in the index:
Age: Good for younger than 60 years, bad for older than 60 years
Step: Good for stage I or II, bad for phase III or IV
Hemoglobin: Good for 125 g/L or more, bad for less than 125 g/l
Lymph node Participation: good for 4 or less, bad for more than 4 knots
LDH: Good for normal LDH, bad for increased LDH.
Patients are assigned an index scratch based on the number of factors for which they are categorized as poor. Therefore, a lower stripe is associated with a more positive prognosis. Patients with a score of 4 or 5 have a 10-year survival rate of 36%, while those with a 0-1 streak have a survival rate of 71%.
Epidemiology
Follicular lymphoma is a type of non-Hodgkin's lymphoma (NHL), which is the fifth most common type of cancer diagnosed in the United States. According to the Cancer Association of America, it is estimated that 72,000 cases of non-Hodgin lymphoma will present in 2016. Of the latter, follicular lymphomas account for about 1 in 5 cases; More than 14,000 cases.
The incidence of non-Hodgkin's lymphoma is higher in more developed countries when age is set. There is a particularly limited impact in some countries, such as China and Japan. People of certain ethnic backgrounds are to be affected, such as those of Jewish origin.
Males and females appear to be also affected by follicular lymphoma, including relapsed and refractory forms of the disease. Older people have a higher risk of follicular lymphoma and the average age for diagnosis is between 60 and 65 years. In accordance with this, the disease is very rare in children and adolescents.
0 comments:
Post a Comment